59 terminated. 59 Phase 2, 17 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 59 | Terminated 59 |
| Phase 1 | 17 | Terminated 17 |
| Phase 3 | 1 | Terminated 1 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Renal Failure | Phase 2 | Terminated | Emory University | 17 | 2020-05-07 | 2024-07-01 |
| Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission GM-CSF vaccine, Lenalidomide, Prevnar13 - Multiple Myeloma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2019-09-23 | 2025-08-27 |
| Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Ixazomib, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 19 | 2019-03-01 | 2023-10-25 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL Venetoclax, Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | TG Therapeutics, Inc. | 78 | 2018-03-27 | 2022-08-22 |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | Yvonne Efebera | 1 | 2018-03-21 | 2019-05-30 |
| Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Lenalidomide, Pembrolizumab - Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 3 | 2017-03-29 | 2021-12-30 |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Ixazomib, Lenalidomide, Rituximab - B Cell Lymphoma, Lymphoma | Phase 1 / Phase 2 | Terminated | Brian Hill | 19 | 2017-02-20 | 2022-09-26 |
| Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Pembrolizumab, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Hackensack Meridian Health | 12 | 2016-12-12 | 2023-08-22 |
| Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Pembrolizumab, Lenalidomide - Relapsed Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 6 | 2016-08-29 | 2020-08-14 |
| Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | University Hospital, Toulouse | 46 | 2016-08-05 | 2020-11-12 |
| Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Lenalidomide, Vorinostat, Gemcitabine - Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2016-06-22 | 2019-12-13 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Revlimid, Velcade, dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 6 | 2016-06-14 | 2018-07-24 |
| Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Lenalidomide, Obinutuzumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2016-03-31 | 2022-09-28 |
| Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine - Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Mayo Clinic | 12 | 2015-06-11 | 2021-01-19 |
| Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Carfilzomib, Dexamethasone, Prednisone - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-12-01 | 2023-11-01 |
| Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Influenza Vaccine, Pneumovax Vaccine - Hematologic Disorder | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-11-24 | 2018-09-20 |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Lenalidomide, nab-paclitaxel - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 3 | 2014-03-01 | 2018-10-15 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Laboratory Biomarker Analysis, Lenalidomide - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 3 | 2013-12-01 | 2020-05-14 |
Showing 20 of 59. Sign in to see all of them.
Multiple Myeloma (18) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Myelodysplastic Syndromes (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Recurrence (6) · Lymphoma, Large B-Cell, Diffuse (5) · Leukemia (4) · Lymphoma, Follicular (3) · Waldenstrom Macroglobulinemia (3) · Bronchiolitis Obliterans Syndrome (2) · Burkitt Lymphoma (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2)
M.D. Anderson Cancer Center (7) · Celgene Corporation (3) · NYU Langone Health (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Celgene (2) · Duke University (2) · Hackensack Meridian Health (2) · Mayo Clinic (2) · Oncotherapeutics (2) · Stanford University (2) · University of California, Davis (2) · Weill Medical College of Cornell University (2) · Albert Einstein College of Medicine (1) · Amgen (1) · Brian Hill (1)
United States (50) · Germany (5) · Australia (3) · Italy (3) · Belgium (2) · France (2) · Canada (1) · Japan (1) · South Korea (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Bruno Carneiro de Medeiros (2) · Adrian Bloor (1) · Alessandra Ferrajoli (1) · Alessandra Ferrajoli, MD,BS (1) · Amin Alousi, MD (1) · Amitabha Mazumder, MD (1) · Amy DeZern, MD (1) · Andrew Spencer, MD (1) · Ann Mohrbacher, MD (1) · Annamaria Brioli, MD (1) · Anne W. Beaven, MD (1) · Anthony Mato, MD (1) · Brian Hill, MD, PhD (1) · Catherine Diefenbach, MD (1)
PMID 19118065, PMID 21504290, PMID 23731832, PMID 24244261, PMID 24244687, PMID 24606326, PMID 24914044, PMID 25052451, PMID 25283471, PMID 27790720, PMID 30190454, PMID 37871300
2009 (3), P30CA013330 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA036727 (1), P30CA138292 (1)